Another phase 1 clinical trial (NCT06325748) is currently enrolling adult patients with R/R CD33 and/or FLT3 expressing heme malignancies for allogenic treatment using SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy candidate that selectively targets hematologic malignancies, using three technologies: 1) the OR GATE, which is an activating CAR that targets either or both CD33 and FLT3, 2) the NOT GATE, which recognize and protect healthy cells from being killed. This evidence concerns the gene CD33 and hematologic disorder.